Baymatob

About

Baymatob develops Oli, a wearable medical device for postpartum haemorrhage, holds FDA Breakthrough Device designation, has a 22-person team, joined ANDHealth+ and runs a large Australian clinical trial.

Mission

Baymatob is developing Oli, a world‑first wearable medical device aimed at tackling postpartum haemorrhage (PPH). The company’s chief visionary officer, Sarah McDonald, is a Sydney doctor and engineer who spent nine years developing the device. Oli has been granted breakthrough device designation by the U.S. Food and Drug Administration. Baymatob’s team is 22 people and the company was selected for the federal ANDHealth+ digital health commercialisation program. In March the company completed a Series A capital raise whose proceeds are being used to fund the largest Australian human clinical trial of the device. Alberts Impact Ventures is an investor and lists Baymatob in its portfolio.

Quick Facts